Development of tamper deterrent formulations: state of the pharmaceutical industry.
Prescription drug abuse is a significant and growing health and socio-economical problem in the US and the world. According to the 2008 UN World Drug Report, the number of people who have consumed an illicit drug at least once in 2006/2007 reached 240 million, roughly 6% of the world population aged 15 to 64. In the last few years, pharmaceutical manufacturers started developing new formulations specifically designed to provide tamper deterrent features. The initial focus of these development activities was extended release opioids, owing to their dominant share of reported prescription drug abuse. Tamper deterrent formulations (TDF) for other drugs of abuse, including stimulants and sedatives are also in various stages of development. Three major challenges face the development of TDF: the increased sophistication of the tampering methods used by abusers, the ambiguity of the regulatory requirements for labeling and marketing and the exaggerated expectations of what these formulations can deliver. This review details the approaches used by pharmaceutical manufacturers to impart tamper deterrent features into their formulations; the in vitro and in vivo tests that have been proposed or used to assess the performance of TDF; and the current regulatory landscape.
CIMA Labs Inc., A Cephalon Company, Brooklyn Park, MN 55428, USA. ehab.hamed@cimalabs.com
Ehab
E
Hamed
Derek
D
Moe
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects; D002492:Central Nervous System Depressants / Q000008:administration & dosage* / Q000009:adverse effects; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D015195:Drug Design; D004345:Drug Industry / Q000379:methods; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control; D006801:Humans; D055553:Prescription Drugs / Q000008:administration & dosage / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000517:prevention & control
D000701:Analgesics, Opioid; D002492:Central Nervous System Depressants; D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D055553:Prescription Drugs